LOS ANGELES, CA / ACCESS Newswire / January 31, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
NDAQ:AZN) AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
NDAQ:PCRX) Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
Arthur J. Gallagher & Co . (NYSE:AJG) reported its Q4 2024 earnings, surpassing analysts' expectations with an adjusted EPS of $2.51, compared to the forecasted $2.06. The company's revenue reached $2.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
IAS Investors Have Opportunity to Lead Integral Ad Science Holding Corp. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a
Highlighting a 55% Increase in Tesla Users, Now Over 700K+ Since Jan. 1st- Including 350K+ Ad-Supported Tesla Users- $40+M in New B2B
LiveOne (Nasdaq: LVO), an award-winning, creator-first, music, entertainment, and technology platform, is pleased to report Chairman and CEO, Robert Ellin, will be presenting at Trump Mar-O-Lago, Florida,
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive